Quasi-equity operation to support, under InnovFin, a Danish pharmaceutical company primarily focused on the development of new antibiotics for the treatment of resistant bacteria; Alexander Stubb, EIB Vice-President; Rasmus Toft-Kehler, Chief Executive Officer, AntibioTx; Morten Sommer, Chief Scientific Officer, AntibioTx